153,130 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Bought by Strs Ohio

Key Points

• Strs Ohio invested approximately $2.35 million in a new position of 153,130 shares of Teva Pharmaceutical Industries Ltd. during the first quarter of 2023.
• Several hedge funds significantly increased their stakes in TEVA, including Harel Insurance, which boosted its position by 197,885.2%, now owning over 22 million shares valued at approximately $339 million.
• Equities analysts maintain a consensus rating of "Buy" for Teva, with a target price averaging around $24.71, indicating confidence in the company's growth prospects despite recent stock price fluctuations.

Strs Ohio acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 153,130 shares of the company's stock, valued at approximately $2,354,000.

Several other institutional investors and hedge funds have also made changes to their positions in TEVA. Ameriprise Financial Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 3.9% during the fourth quarter. Ameriprise Financial Inc. now owns 147,649 shares of the company's stock worth $3,254,000 after buying an additional 5,494 shares during the period. Focus Partners Wealth lifted its stake in shares of Teva Pharmaceutical Industries by 8.7% during the fourth quarter. Focus Partners Wealth now owns 38,335 shares of the company's stock worth $845,000 after buying an additional 3,071 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Teva Pharmaceutical Industries by 122.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,048 shares of the company's stock valued at $221,000 after purchasing an additional 5,526 shares during the period. Nuveen Asset Management LLC lifted its position in Teva Pharmaceutical Industries by 6.8% during the fourth quarter. Nuveen Asset Management LLC now owns 2,857,007 shares of the company's stock valued at $62,968,000 after purchasing an additional 182,774 shares during the period. Finally, Man Group plc lifted its position in Teva Pharmaceutical Industries by 191.7% during the fourth quarter. Man Group plc now owns 43,302 shares of the company's stock valued at $954,000 after purchasing an additional 28,457 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Teva Pharmaceutical Industries

In related news, insider Eric A. Hughes sold 52,742 shares of the company's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Placid Jover sold 6,053 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the sale, the insider directly owned 6,774 shares in the company, valued at approximately $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.49% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Stock Down 0.4%

TEVA traded down $0.07 during trading hours on Friday, hitting $18.38. 7,435,534 shares of the company's stock were exchanged, compared to its average volume of 9,410,089. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $22.80. The firm has a 50 day moving average of $17.51 and a 200 day moving average of $16.58. The firm has a market cap of $21.08 billion, a P/E ratio of -114.88, a price-to-earnings-growth ratio of 1.07 and a beta of 0.72. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. During the same period in the prior year, the firm earned $0.61 EPS. The firm's revenue for the quarter was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on TEVA. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. UBS Group decreased their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Finally, The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of "Buy" and an average target price of $24.71.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.